Evgeniy P. Evdoshenko

Evgeniy P. Evdoshenko

Auto-generated profile, based on publicly available information

Evgeniy P. Evdoshenko

City Clinical Hospital No. 31

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MBMarina Kleopatra Boziki
Marina Kleopatra Boziki
AMAlexios-Fotios Mentis
Alexios-Fotios Mentis
MSMaria Shumilina
Maria Shumilina
GMGleb Makshakov
Gleb Makshakov
EEEvgeniy Evdoshenko
Evgeniy Evdoshenko
NGNikolaos Grigoriadis
Nikolaos Grigoriadis
In the frame of the coronavirus disease 2019 (COVID-19) pandemic, recent reports on SARS-CoV-2 potential neuroinvasion placed neurologists on increased alertness in order to assess early neurological manifestations and their potentially prognostic value for the COVID-19 disease. Moreover, the management of chronic neurological diseases, such as Multiple Sclerosis (MS), underwent guided modifications, such as an Extended Interval Dose (EID) of Disease-Modifying Treatment (DMT) administration, in order to minimize patients’ exposure to the health system, thus reducing the risk of SARS-CoV-2 infection. In this review, we summarize existing evidence of key immune pathways that the SARS-CoV-2 modifies during COVID-19 and the relevant implication for MS and other autoimmune diseases with associated demyelination (such as Systemic lupus erythematosus and Antiphospholipid syndrome), including the context of potential neuroinvasion by SARS-Cov-2 and the alterations that DMT induces to the immune system. Moreover we hereby aim to provide an overview of the possible consequences that COVID-19 may carry for the Central Nervous System (CNS) in People with MS (PwMS) and other demyelinating diseases, which are likely to pose challenges for treating Neurologists with respect to the long-term disease management of these diseases.

1 December 2018 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
VNVladimir Nazarov
Vladimir Nazarov
GMGleb Makshakov
Gleb Makshakov
IKIvan Kalinin
Ivan Kalinin
SLSergey Lapin
Sergey Lapin
ESElena Surkova
Elena Surkova
EEEvgeniy Evdoshenko
Evgeniy Evdoshenko

20 December 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
VKV. S. Krasnov
V. S. Krasnov
KBK. Z. Bakhtiyarova
K. Z. Bakhtiyarova
EEE. P. Evdoshenko
E. P. Evdoshenko
DKDenis Korobko
Denis Korobko
TST. O. Simaniv
T. O. Simaniv
MDM. V. Davydovskaya
M. V. Davydovskaya
Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy

16 June 2021 in Journal of the International Neuropsychological Society
Verified
Journal Article
Closed access
PDF file
EEEvgeniy Evdoshenko
Evgeniy Evdoshenko
KLKristina Laskova
Kristina Laskova
MSMaria Shumilina
Maria Shumilina
ENEkaterina Nekrashevich
Ekaterina Nekrashevich
MAMaria Andreeva
Maria Andreeva
GMGleb Makshakov
Gleb Makshakov
Objective: Cognitive dysfunction is common in multiple sclerosis (MS). The Brief International Cognitive Assessment for MS (BICAMS) battery of tests has been suggested as a measure for the evaluation of the cognitive status of MS patients. This study aims to validate the BICAMS battery in the Russian population of MS patients.Methods: Age- and sex-matched MS patients (n = 98) and healthy individuals (n = 86) were included in the study. Symbol Digit Modalities Test (SDMT), California Verbal Learning Test, 2nd edition (CVLT-II) and the Brief Visuospatial Memory Test – Revised (BVMT-R) were administered to all participants. The battery was readministered 1 month later to 44 MS patients to investigate the test–retest reliability.Results: MS patients exhibited a significantly lower performance in testing with BICAMS than the control group in all three neuropsychological tests. Test–retest reliability was good for SDMT and CVLT-II (r = .82 and r = .85, respectively) and adequate for BVMT-R (r = .70). Based on the proposed criterion for impairment as z score below 1.5 SD the mean of the control group, we found that 34/98 (35%) of MS patients were found impaired at least in one cognitive domain. Patients with Expanded Disability Status Scale score ≥3.5 performed significantly worse than controls (SDMT, p < .0001; CVLT–II, p = .03; BVMT-R, p = .0004), while those with ≤3.0 scores did not.Conclusion: This study demonstrates that the BICAMS battery is a valid instrument to identify cognitive impairment in MS patients and it can be recommended for routine use in the Russian Federation.

7 May 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
IKI. Kalinin
I. Kalinin
GMGleb Makshakov
Gleb Makshakov
EEE. Evdoshenko
E. Evdoshenko
BACKGROUND AND PURPOSE: Recent studies showed thalamic atrophy in the early stages of MS. We investigated the impact of intracortical lesions on the volumes of subcortical structures (especially the thalamus) compared with other lesions in MS. MATERIALS AND METHODS: Seventy-one patients with MS were included. The volumes of intracortical lesions and white matter lesions were identified on double inversion recovery and FLAIR, respectively, by using 3D Slicer. Volumes of white matter T1 hypointensities and subcortical gray matter, thalamus, caudate, putamen, and pallidum volumes were calculated using FreeSurfer. Age, MS duration, and the Expanded Disability Status Scale score were assessed. RESULTS: Patients with intracortical lesions were older (P = .003), had longer disease duration (P < .001), and higher Expanded Disability Status Scale scores (P = .02). The presence of intracortical lesions was associated with a significant decrease of subcortical gray matter volume (P = .02). In our multiple regression model, intracortical lesion volume was the only predictor of thalamic volume (R2 = 0.4, b* = –0.28, P = .03) independent of white matter lesion volume and T1 hypointensity volume. White matter lesion volume showed an impact on subcortical gray matter volume in patients with relapsing-remitting MS (P = .04) and those with disease duration of <5 years (P = .04) and on thalamic volume in patients with Expanded Disability Status Scale scores of <4.0 (P = .01). By contrast, intracortical lesion volume showed an impact on subcortical gray matter and thalamic volumes in the secondary-progressive MS subgroup (P = .02 and P < .001) in patients with a long-standing disease course (P < .001 and P = .001) and more profound disability (P < .001 and P < .001). CONCLUSIONS: Thalamic atrophy was explained better by intracortical lesions than by white matter lesion and T1 hypointensity volumes, especially in patients with more profound disability.

28 May 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EEEvgeniy Evdoshenko
Evgeniy Evdoshenko
ASAlexandra Stepanova
Alexandra Stepanova
MSMaria Shumilina
Maria Shumilina
MDMaria Davydovskaya
Maria Davydovskaya
NKNatalia Khachanova
Natalia Khachanova
GMGleb Makshakov
Gleb Makshakov
NTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far. To characterize the population of patients receiving natalizumab and assess the efficacy and risk-management plan (RMP) implementation of NTZ therapy in routine clinical practice in Russia. We analyzed data for 334 patients, who received at least one infusion of NTZ. Relapse rate, MRI activity, NEDA-3 status after 2 years were assessed. Anti-JC virus antibodies status and RMP implementation were evaluated. Drop-out rate and reasons for therapy discontinuation were analyzed. Patients switched to natalizumab in Russia are mainly female (63%), with median EDSS score of 3.5 and high disease activity: 93% had at least 1 relapse and 58% had both T1Gd+ and new T2 lesion a year before therapy initiation. Introduction of federal reimbursement allowed patients with less relapses to start therapy with natalizumab. The only predictor of 6-month progression was EDSS score at the baseline of therapy (HR = 2.1375, 95%CI 1.0026–4.5570, p = 0.0492). 82% patients reached NEDA-3 at 24 month of therapy. 25% of patients discontinued NTZ for reasons: tolerability (14.5%), JCV antibody status (61%), and patient’s decision (17%). RMP was implemented in only 36% patients. Natalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation.